Maman Ibrahim is a cyber and digital risk executive, helping boards, CRO, CIO, and CISO turn risk work into decisions, delivery, and proof.gettyIn my work advising pharmaceutical leadership teams on risk governance, I see the same pattern recur with surprising regularity: a third-party clinical platform suffers a control failure. Trial data is exposed through a poorly secured interface, or a contracted research partner mishandles regulated records.Within hours, five functions are discussing the incident, each describing it in the language of its own discipline. Cyber treats it as an intrusion. The regulatory team frames it as a trial data integrity issue requiring notification to authorities. Legal records it as exposure of sensitive scientific material. Finance models the impact on pipeline value. Vendor risk recognizes it as a third-party governance failure, but its perspective is folded quietly into the broader discussion.​In many cases, the vendor risk perspective is the one most directly aligned with where the underlying failure occurred.​ However, in most risk registers I have reviewed, teams log the same event under cyber, regulatory or operational risk, while reducing the vendor dimension to a footnote. The result is a register that captures the consequences of a failure but loses the cause.​Why The Root Cause Gets Lost In The Response​​It is natural for a function to claim ownership of a risk when it is absorbing the impact. When regulators question trial data integrity, regulatory manages the authority response. When attackers exploit a weak interface, cyber leads the remediation. When commercial value shifts, finance carries the model. Pain, however, is not the same as origin. A vendor governance failure that produces cyber, regulatory and commercial consequences remains, at its root, a vendor governance failure. The consequences are real and require active management, but they are attributes of the event, not the event itself.This distinction can be uncomfortable in practice. Reclassifying a risk that has sat in the cyber register for years as a third-party event can, to the team that has been managing it, feel like a demotion. In my experience, the best response is to frame classification as a question of accuracy rather than ownership. The function that absorbs the consequence remains accountable for managing it; what changes is how the board sees the underlying pattern across multiple incidents.The Governance Locus TestThe most useful question I ask leadership teams is straightforward: Where did the control, contract, assurance, access, evidence or monitoring fail? Not where the loss appeared or which function raised the first alarm, but where the breakdown in governance originated. I call this the governance locus, and leaders must identify it before anyone logs the event.​If the event falls within a vendor relationship, classify it as a third-party event, then record the cyber, regulatory, legal and commercial dimensions beneath it as attributes. The cyber attribute describes the attack path through weak access controls. The regulatory attribute records the integrity review and notification obligation. The legal attribute captures the exposure of scientific material. The commercial attribute models the pipeline scenario, kept separate because it depends on future triggers. The board then sees a single event with multiple connected consequences rather than a collection of unrelated risks.​Why Pharma Is Particularly ExposedPharmaceutical companies depend on third parties for some of their most sensitive obligations. Clinical research organizations, trial platforms, laboratory systems, safety databases, manufacturing partners and cloud vendors all touch patient data, regulated evidence, manufacturing records, safety signals and valuable intellectual property. These relationships often involve transferring regulated activity to another organization under contract. When one of these partners fails, the consequences typically spread across the cyber, regulatory, legal, supply chain and commercial domains simultaneously. That spread is precisely why correct classification matters: a register that consistently logs vendor-driven events under their downstream consequences will never reveal the systemic vendor assurance weaknesses underneath. You cannot fix a pattern you keep misfiling.What Changes When Vendor Governance Becomes PrimaryWhen boards begin to treat vendor governance as a primary risk domain, several practical things are likely to change. Similar vendor events may start to group rather than being scattered across the register. Repeated access-control failures across clinical platforms become apparent as a pattern. Weak notification clauses, limited audit rights and inconsistent assurance testing surface as enterprise control gaps rather than isolated procurement issues.Investment decisions can improve, too. When teams classify a series of events as cyber breaches, leaders tend to fund more cyber tooling, which may or may not fix the underlying weakness. If teams classify the same events as third-party governance failures, the board can ask sharper questions: • Which vendors hold regulated trial data?• Which contracts give us meaningful audit rights?• Which platforms lack access segregation?• Which suppliers must notify us within agreed timeframes?• Which assurance tests examine the controls that matter?Practical Steps For Leadership TeamsFor boards and executive teams looking to operationalize this, I suggest four steps: 1. Review recent incidents classified as cyber, regulatory, legal, operational or supply chain risks, and identify those in which the initial failure sat with a vendor. 2. Create a visible third-party event domain in the risk register, positioned at the same level as cyber or regulatory risk rather than buried under operational risk. 3. Define vendor event families in plain language: clinical platform security failure, CRO oversight failure, vendor access control failure, GxP system assurance failure and vendor incident notification failure. 4. Train risk and assurance teams to ask the governance locus question consistently before they log any event.In ConclusionA vendor-driven pharmaceutical event should be classified by where governance failed, not by which function experiences the most visible impact or reports the largest financial exposure. Done consistently, this lets the board see the system behind each incident. It does not turn vendor risk into the story's hero. It simply ensures that the risk story begins where governance failed.​​Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?